

**Sterne Kessler  
Goldstein Fox**  
ATTORNEYS AT LAW



Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbalà  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millionig  
Lawrence B. Bugalsky  
Donald J. Featherstone  
Michael V. Messinger

Judith U. Kim  
Timothy J. Shea, Jr.  
Patrick E. Garrett  
Jeffery T. Helvey\*  
Heidi L. Kraus  
Crystal D. Sayles  
Edward W. Yee  
Albert L. Ferro\*  
Donald R. Banowitz  
Peter A. Jackman  
Molly A. McCall  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Albert J. Fasulo II\*  
Eldora Ellison Floyd  
W. Russell Swindell

Thomas C. Fiala  
Brian J. Del Buono  
Virgil Lee Beaton\*  
Reginald D. Lucas\*  
Kimberly A. Reddick  
Theodore A. Wood  
Elizabeth J. Haanes  
Bruce E. Chalker  
Joseph S. Ostroff  
Frank R. Cottingham\*  
Christine M. Uhlfier  
Rae Lynn Prengaman\*  
Jane Shershenovich\*  
Lawrence J. Carroll\*  
George S. Bardmesser

Registered Patent Agents\*  
Karen R. Markowicz  
Andrea J. Kamage  
Nancy J. Leith  
Joseph M. Conrad III  
Ann E. Summerfield  
Helene C. Carlson  
Gaby L. Longworth  
Matthew J. Dowd  
Aaron L. Schwartz  
Angelique G. Uy  
Boris A. Matvenko  
Mary B. Tung  
Katrina Y. Pei  
Bryan L. Skelton  
Jason D. Eisenberg  
John J. Figueroa

Senior Counsel  
Samuel L. Fox  
Kenneth C. Bass III  
Lisa A. Dunner

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Admitted only in Texas  
\*Practice Limited to  
Federal Agencies

July 26, 2002

RECEIVED

JUL 29 2002

TECH CENTER 1600/2900

WRITER'S DIRECT NUMBER:

(202) 371-2673

INTERNET ADDRESS:

JCOVERT@SKGF.COM

Commissioner for Patents  
Washington, D.C. 20231

Art Unit 1614

Re: U.S. Utility Patent Application  
Appl. No. 10/058,215; Filed: January 29, 2002  
For: **Substituted Indoles and Their Use as Integrin Antagonists**  
Inventors: Lu *et al.*  
Our Ref: 1503.1030002/JMC/THN/JSL

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. List of cited documents on Form PTO-1449 (15 sheets);
3. Copies of cited documents listed on Form PTO-1449 (52 documents);
4. First Supplemental Information Disclosure Statement;
5. List of cited documents on Form PTO-1449 (2 sheets) for First Supplemental Information Disclosure Statement;
6. Copies of cited documents listed on Form PTO-1449 (16 documents) for First Supplemental Information Disclosure Statement; and
7. Return postcard.

Commissioner for Patents

July 26, 2002


Page 2

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



John M. Covert  
Attorney for Applicants  
Registration No. 38,759

JMC/JSL/asl  
Enclosures

SKGF\_DC1:38375.1

#4 (22)  
8/3/2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

Lu *et al.*

Appl. No. 10/058,215

Filed: January 29, 2002

For: **Substituted Indoles and Their Use  
as Integrin Antagonists**

Confirmation No. 2206

Art Unit: 1614

Examiner: *To be assigned*

Atty. Docket:  
1503.1030002/JMC/THN/JSL

**Information Disclosure Statement**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

**RECEIVED**  
JUL 29 2002  
TECH CENTER 1600/2900

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of these documents is provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application

does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

Document AM1, originally in the German language, is submitted herewith as a verified English translation thereof (Australian Patent Appl. 13016/97).

Document AP1 is in a foreign language. The significance of document AP1 can be ascertained by reference to 1) the English language summary appearing in the front page of the document; and 2) document AT15, which is the Chemical Abstracts English language summary of document AP1.


It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



John M. Covert  
Attorney for Applicants  
Registration No. 38,759

Date: July 26, 2002

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

Lu *et al.*

Appl. No. 10/058,215

Filed: January 29, 2002

For: **Substituted Indoles and Their Use  
as Integrin Antagonists**

Confirmation No. 2206

Art Unit: 1614

Examiner: *To be assigned*

Atty. Docket:  
1503.1030002/JMC/THN/JSL

**First Supplemental Information Disclosure Statement**

Commissioner for Patents  
Washington, D.C. 20231

**RECEIVED**

JUL 29 2002

TECH CENTER 1000/29000

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed herewith in connection with the above-captioned application. A copy of each document is also provided.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following concise explanations of relevance of non-English language document AM3 cited on Form PTO 1449:

Document AM3 is in a foreign language. The significance of document AM3 can be ascertained by reference to 1) the English language summary appearing in the front page of the document; and 2) document AR17, which is the Derwent WPI English language abstract of document AM3.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates

should not be construed as an admission that the information was actually published on the date indicated.


Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This First Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



John M. Covert  
Attorney for Applicants  
Registration No. 38,759

Date: July 26, 2002

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600